首页 > 市场调查报告书 > 製药

临床实验

市场调查报告书

商品编码

1140743

全球动静脉瘘市场-2022-2029

Global Arteriovenous Fistula Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

对先进治疗的需求不断增长

在预测期内，随着参与者开发新的疗法，如光动力疗法、血管生成疗法和其他硬化疗法，预计动静脉瘘护理市场将扩大。以简单的方式实现完全康復的成功治疗形式仍在开发中，促使玩家提出创新的治疗技术。此外，增加 FDA 对用于动静脉瘘形成的非侵入性设备的批准推动了预测期内的市场增长。

此外，众所周知，血液透析的最佳途径是自製动静脉瘘。另一方面，外科动静脉瘘的构建是技术能力差的代名词，可能需要多个程序来帮助成熟和保持初始通畅。经常有。由于这些缺点，目前正在研究许多可以改善手术程序和性能的新方法。正在研究製造新的微创系统的方法，并取得了初步成果。此外，研究管道中大量治疗药物的存在和乐观的政府政策预计将在预测期内改善对动静脉瘘的需求。

市场发展是由改进的治疗方法驱动的，例如血管生成、光动力疗法和辅助形式的硬化疗法。为这种疾病的全面治疗制定适当的治疗计划是一个持续且困难的过程。这就产生了对行业领导者提出的新技术和改进处理工艺的需求。市场发展因对该疾病的低认识而受到阻碍。

然而，缺乏能够解决动静脉瘘具体原因的有效治疗剂将限制市场的扩大。恢復通常需要比预期更长的时间或访问不成熟。此外，需要一根针来进入动静脉瘘进行透析。

地理渗透。

北美地区有望主导全球动静脉瘘市场

该研究按地区分析了全球市场的动静脉瘘市场，包括北美、欧洲、亚太地区、南美、中东和非洲。

在地理上，由于美国政府积极主动地为动静脉瘘疾病开发新的治疗药物，北美在全球动静脉瘘市场处于领先地位。欧洲动静脉瘘市场是仅次于美国的第二大市场。欧洲动静脉瘘市场的增长主要是由于该地区动静脉瘘发病率的增加以及对动静脉瘘治疗的旺盛需求。

此外，亚太国家因其先进的医学水平，被定位为世界动静脉瘘的发展中国家。

竞争格局。

由于美国、中国和印度等关键地区的主要市场参与者的存在，动静脉瘘市场保持适度竞争。对全球市场增长做出贡献的主要动静脉瘘製造商包括 Pervasis Therapeutics, Inc.、Proteon Therapeutics, Inc.、Medtronic、Cook Medical、Fresenius Medical Care AG &Co.KGaA、Poly Medicure Limited、Becton Dickinson and Company、Braun Melsungen Ag , Teleflex 公司等领先公司正在为全球动静脉瘘市场的增长采用新产品推出和扩张战略。2020年9月，全球医疗技术领导者美敦力收购了私营医疗器械公司Avenue Medical。Avenue的经皮瘘管技术增强了medtronic的外周通路产品组合，并强化了medtronic改善终末期肾病患者预后的承诺。2020 年 9 月，medtronic通过收购 Avenu Medical 扩大了其透析通路的地位。该公司将收购 Avenu Medical，该公司生产一种系统，可为需要建立透析通路的终末期肾病患者创建微创动静脉 (AV) 瘘管。2020 年 1 月，Cook Medical 和 Bentley 宣布了一项临床试验合作战略，涉及 Cook 的栅栏和分支支架移植物以及 Bentley 的覆膜支架。

COVID-19 的影响。对全球动静脉瘘市场的负面影响。

全球医疗保健系统正受到最近被称为 2020 年冠状病毒病 (COVID-19) 的流行病的挑战。到 4 月初，已有超过 100 万例阳性病例登记，51,737 人死亡。在大流行期间，维持医疗基础设施的全球解决方案至关重要。推迟选择性治疗的最大理由是让卫生系统为大流行做好准备。关于是否应该推迟血管手术以及护理 COVID-19 患者所需的安全措施，已经提出了各种问题。此外，血液透析的血管通路被认为是患者的生命线，其维护对于护理的一致性至关重要。巴西肾脏病学会跟随其他受 COVID-19 流行影响的国家的组织的脚步，为医疗保健机构制定了这些建议，强调了实施程序以规划和保护血管通路的价值。我详细解释了。非选择性治疗以及从非隧道式导管到发病率较低的隧道式导管的过渡是血液透析、移植物和动静脉瘘的关键通路发展。

全球动静脉瘘市场报告提供对大约 53 个市场数据表、40 个数字和 170 页的访问。

Pervasis Therapeutics, Inc.
- 公司简介
- 产品组合和描述
- 主要亮点
- 财务摘要
Proteon Therapeutics, Inc.
Medtronic,
Cook Medical
Fresenius Medical Care AG & Co. KGaA
Poly Medicure Limited
Becton Dickinson and Company
Braun Melsungen Ag
Teleflex Incorporated
NxStage Medical, Inc.（*LIST NOT EXHAUSTIVE）

第 12 章重要注意事项

第 13 章数据管理

简介目录

Product Code: DMPH3137

Market Overview

Arteriovenous Fistula Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Sub-Domain: Others

The interruption of blood supply caused by an irregular link between a vein and an artery is known as an arteriovenous fistula. Blood passes straight from lungs to veins in the event of an arteriovenous fistula, bypassing capillaries. Capillary tissues thus obtain smaller supplies of oxygen (blood supply) and raise the risk of complications with blood pressure. Fistulas between the arteries and veins may be congenital or inherited. Congenital fistula occurs during embryonic development and mainly affects blood vessels in the lower extremities. While acquired fistula typically happens when veins and arteries are impaired, the healing process results in two parallel vein and artery connections. Further, the arteriovenous fistula is formed on the arms, kidneys, brain, or certain parts of the legs. Penetrating damage, arterial vein breakup, and inflammatory necrosis of adjacent veins all increase the risk of an arteriovenous fistula. With consistent efforts of key players to develop novel therapeutics for the treatment of arteriovenous fistula, the global arteriovenous fistula market is seeing fast growth in the forecast period.

Market Dynamics: Growing demand for advanced treatment methods

Over the projected period, the arteriovenous fistulas care market is expected to expand as players develop new treatment methods such as photodynamic therapy, antiangiogenic therapy, and other sclerotherapy methods. The successful form of therapy for a complete recovery in a simple way is still in the development process, which inspires players to come up with innovative treatment technologies. Further, growing FDA approvals for noninvasive devices for arteriovenous fistula creation have resulted in the market growth over the forecast period.

Moreover, the optimal access for hemodialysis transmission is known to be an autogenous arteriovenous fistula. On the other hand, the surgical development of an arteriovenous fistula is synonymous with less-than-ideal technical performance, and numerous procedures are often required to aid maturation or preserve early patency. With these deficiencies, many new methods are now under study that can enhance surgical procedures and/or performance. Minimally invasive new system manufacturing methods are being studied, with early research findings available. Furthermore, the presence of a vast number of therapeutics in the research pipeline and optimistic government policies would improve the demand for arteriovenous fistula over the forecast period.

Market players are improving their treatment approaches, such as antiangiogenic therapy, photodynamic therapy and an additional form of sclerotherapy, as factors contributing to this development. Developing an appropriate therapeutic plan for the full treatment of the condition is a challenging process still in progress. It generated the need for new technologies and improvements in the treatment process for industry leaders to come up with. The market's development is hampered by a lack of awareness about the disease.

However, the lack of effective therapeutics that can address the particular cause of arteriovenous fistula, the other hand, would restrict the market's expansion. Often recovery may take longer than expected, or access can fail to mature. Further, to access the AV fistula for dialysis, needles are required.

Market Segmentation: The radial cephalic fistula segment is projected to be the dominant segment in the market during the forecast period.

Based on the type, the arteriovenous fistula market has been classified into the radial cephalic fistula, brachial cephalic, brachial basilic transposition.

As part of the Kidney disease outcomes quality initiative (KDOQI), the 2006 recommendations suggested by the National Kidney Foundation suggest that a radiocephalic fistula be the first alternative for fistula creation. This is because the radiocephalic fistula has a lower rate of steal syndrome than upper arm fistulas and because developing this forearm fistula retains the possibility of creating a more proximal fistula in the future if this access fails. The maturation rate for radiocephalic fistulas, however, is low, with one analysis finding that up to two-thirds of radiocephalic fistulas have not matured.

The global arteriovenous fistula market is segmented based on treatment methods, which includes endovascular embolization, microsurgery, stereotactic radiosurgery.

The endovascular embolization segment is expected to account for a significant market share in the Arteriovenous Fistula market. Endovascular embolization is a recent therapeutic procedure for arteriovenous malformations (AVM). During this procedure, a catheter is implanted through the groin into the arteries in the brain that contribute to the AVM, and material is injected into the arteries. This injection blocks the artery, limiting blood flow into the AVM. Usually, endovascular embolization alone does not remove the AVM and is, thus, almost exclusively used as a preliminary step in either microsurgical resection or stereotactic radiotherapy preparation.

Geographical Penetration: North America region is expected to dominate the global Arteriovenous Fistula market

Based on geography, the study analyzes the arteriovenous fistula market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Geographically, owing to positive measures by the U.S. government to create new therapeutics for arteriovenous fistula disease, North America leads the worldwide arteriovenous fistula market. Europe is the second-largest market for arteriovenous fistulas after the U.S. The growth of this market in Europe is mainly due to the growing occurrence of arteriovenous fistula in this region, combined with a strong demand for arteriovenous fistula therapy.

Moreover, owing to the growing healthcare understanding among the patient population, Asia-Pacific countries are the developing countries in the worldwide arteriovenous fistula industry.

Competitive Landscape:

The arteriovenous fistula market is moderately competitive, owing to the presence of major market players in key regions such as the US, China, India and others. The key arteriovenous fistula players which are contributing to the growth of the global market include Pervasis Therapeutics, Inc., Proteon Therapeutics, Inc., Medtronic, Cook Medical, Fresenius Medical Care AG & Co. KGaA, Poly Medicure Limited, Becton Dickinson and Company, Braun Melsungen Ag, Teleflex Incorporated among others. The major players are adopting new product launches and expansion strategies for global growth in the arteriovenous fistula market. In September 2020, Medtronic, the global leader in medical technology, acquired Avenue Medical, a privately held medical device company. Avenu's Percutaneous Fistula Creation Technology strengthens the Medtronic Peripheral Vascular Access Portfolio and Reinforces Medtronic's Commitment to Improving Outcomes for Patients with End-Stage Renal Disease. In September 2020, Medtronic expanded its dialysis access position with Avenu Medical buyout. The company plans to acquire Avenu Medical, which produces a system for minimally invasive creation of arteriovenous (AV) fistulae for end-stage renal disease patients who need to establish dialysis access. In January 2020, Cook Medical and Bentley announced their collaboration strategy for a clinical trial involving Cook's fenestrated and branch stent grafts and Bentley's covered stents.

COVID-19 Impact: Negative impact on the global arteriovenous fistula market.

The global healthcare system has been challenged by a recent epidemic known as coronavirus disease 2020 (COVID-19). More than 1,000,000 positive cases had been registered by the beginning of April, with 51,737 deaths. A global solution to sustain the healthcare infrastructure is crucial during a pandemic. The primary justification for delaying elective treatments is ensuring the healthcare system can keep up with the pandemic. There have been various questions about whether to postpone vascular operations and the safety steps needed to care for a patient with COVID-19. Moreover, hemodialysis vascular accesses are considered the patient's lifeline, and their upkeep is vital for care consistency. The Brazilian Society of Nephrology developed these recommendations for healthcare facilities, elaborating on the value of conducting procedures for the planning and protection of vascular accesses, following the lead of organizations in other countries affected by the COVID-19 pandemic. Non-elective treatments, as well as the transition from the use of non-tunnel catheters to tunnel catheters causing less morbidity, are the development of conclusive accesses for hemodialysis, grafts and arteriovenous fistulas.

The global arteriovenous fistula market report would provide an access to approximately 53 market data tables, 40 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Type
3.2. Market Snippet by Treatment Methods
3.3. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing demand for advanced treatment methods
- 4.1.2. Restraints:
  - 4.1.2.1. Lack of effective therapeutics
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
7.3. Market Attractiveness Index, By Type Segment
- 7.3.1. Radial Cephalic fistula
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Brachial Cephalic
- 7.3.3. Brachial Basilic Transposition

8. By Treatment Methods

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods Segment
8.3. Market Attractiveness Index, By Treatment Methods Segment
- 8.3.1. Endovascular embolization
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Microsurgery
- 8.3.3. Stereotactic radiosurgery

9. By Region

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. U.S.
  - 9.4.5.2. Canada
  - 9.4.5.3. Mexico
9.5. Europe
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. Germany
  - 9.5.5.2. U.K.
  - 9.5.5.3. France
  - 9.5.5.4. Italy
  - 9.5.5.5. Spain
  - 9.5.5.6. Rest of Europe
9.6. South America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.6.5.1. Brazil
  - 9.6.5.2. Argentina
  - 9.6.5.3. Rest of South America
9.7. Asia Pacific
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.7.5.1. China
  - 9.7.5.2. India
  - 9.7.5.3. Japan
  - 9.7.5.4. Australia
  - 9.7.5.5. Rest of Asia Pacific
9.8. Middle East and Africa
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Global Arteriovenous Fistula Market- Company Profiles

11.1. Pervasis Therapeutics, Inc.
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Proteon Therapeutics, Inc.
11.3. Medtronic,
11.4. Cook Medical
11.5. Fresenius Medical Care AG & Co. KGaA
11.6. Poly Medicure Limited
11.7. Becton Dickinson and Company
11.8. Braun Melsungen Ag
11.9. Teleflex Incorporated
11.10. NxStage Medical, Inc.(*LIST NOT EXHAUSTIVE)

12. Premium Insights

13. DataM Intelligence Analysis

13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球动静脉瘘市场-2022-2029